Influenza, Human
Conditions
Brief summary
This study evaluates the safety, tolerability and immunogenicity of IL-YANG quadrivalent vaccine versus IL-YANG trivalent vaccine after a single intramuscular administration in healthy Korean males and females 19 to \< 65 years of age.
Detailed description
This is a randomized, double-blind, active-controlled, phase I/Ⅱa clinical trial. During the Part A phase, all safety data collected from the 12 subjects enrolled in the Part A phase will be analyzed to determine the safety and tolerability of the investigational product, which should include any solicited and unsolicited adverse drug reactions occurring for the first 7 days after vaccination and any adverse events occurring for 28 days after vaccination. Antibody titer test will be also performed to evaluate the efficacy (immunogenicity) of the investigational product. During the Part B phase, a total of 72 subjects will be enrolled, and all safety data (including all adverse events) and immunogenicity data will be analyzed.
Interventions
BIOLOGICALIL-YANG Flu Vaccine QIV 0.5mL
BIOLOGICALIL-YANG Flu Vaccine TIV 0.5mL
Sponsors
Il-Yang Pharm. Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
19 Years to 64 Years
Healthy volunteers
Yes
Inclusion criteria
* Healthy men and women 19 to \< 65 years of age at screening * Body weight within ±20% of ideal body weight at screening * Women of childbearing potential must have a negative serum beta-hCG at visit 2; and agree to use a proper contraceptive method for 1 month after vaccination (starting from 3 months before screening), using a medication or device that does not have any drug-interaction with the investigational product. * Subjects with no congenital or chronic disease who were considered suitable for the study after screening assessments (investigator's opinion, medical history, physical examination, laboratory test, chest X-ray, and ECG) conducted no later than 28 days prior to vaccination * Subjects who were given, and fully understood, the information about the study, and have provided voluntary written informed consent to participate in the study and to comply with all applicable study requirements
Exclusion criteria
* Subject with known allergy to eggs, chicken, or any components of the investigational product * Subjects who had received an influenza vaccine within the last 6 months prior to study entry * Subjects who have known or suspected infection with HAV, HBV, HCV, HIV or VDRL * Subjects who have concurrent or a past history of, immune deficiency disease * Subject with a history of Guillain-Barre syndrome * Subject with hemophilia or thrombocytopenia or being treated with an anticoagulant, who are at increased risk of serious bleeding during intramuscular injection * Subjects with known allergy to a drug, food or latex, who had a history of anaphylaxis * Subjects who had an acute fever with body temperature \> 38.0 Cº within 72 hours prior to administration of the investigational product or symptoms of suspected acute disease within 14 days prior to administration of the investigational product * Subjects who had received another vaccine within 28 days before administration of the investigational product or are planning to receive another vaccine during the study. * Subjects who had participated in another clinical trial within the 30 days before administration of the investigational product. * Subjects who had previously received blood-derived products (including immunoglobulin) within the last 3 months prior to administration of the Investigational product, or are scheduled to receive a treatment with blood-derived products during the study * Subjects who had received, or are scheduled to receive, systemic immunosuppressive therapy, radiation therapy or high-dose steroid therapy within the last 6 months prior to administration of the study * Subjects with a history of drug abuse within the last 6 months prior to vaccination, or is suspected of drug abuse * Subjects with excessive consumption of caffeine, alcohol, or tobacco * Subjects with other clinically significant medical or psychiatric illness who in the investigator's opinion, are not be suitable for the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Seroconversion Rate | 28 days | Percentage of subjects achieving seroconversion\* for HI antibody after vaccination |
| Seroprotection Rate | 28 days | Percentage of subjects achieving seroprotection\* for HI antibody after vaccination |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| GMR | 28 days | Geometric Mean Ratio of post vaccination HI geometric mean titers |
| GMT | 28 days | Geometric Mean Titer of post vaccination HI geometric mean titers |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| IL-YANG Flu Vaccine QIV 0.5mL A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine QIV 0.5mL | 56 |
| IL-YANG Flu Vaccine TIV 0.5mL A single 0.5mL dose administrated as an intramuscular injection.
IL-YANG Flu Vaccine TIV 0.5mL | 28 |
| Total | 84 |
Baseline characteristics
| Characteristic | IL-YANG Flu Vaccine QIV 0.5mL | IL-YANG Flu Vaccine TIV 0.5mL | Total |
|---|---|---|---|
| Age, Continuous | 26.77 years STANDARD_DEVIATION 7.01 | 27.75 years STANDARD_DEVIATION 8.48 | 27.10 years STANDARD_DEVIATION 7.5 |
| Sex: Female, Male Female | 11 Participants | 5 Participants | 16 Participants |
| Sex: Female, Male Male | 45 Participants | 23 Participants | 68 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 56 | 0 / 28 |
| other Total, other adverse events | 0 / 56 | 0 / 28 |
| serious Total, serious adverse events | 0 / 56 | 0 / 28 |
Outcome results
Primary
Seroconversion Rate
Percentage of subjects achieving seroconversion\* for HI antibody after vaccination
Time frame: 28 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IL-YANG Flu Vaccine QIV 0.5mL | Seroconversion Rate | H1N1 | 58.93 percentage of participants |
| IL-YANG Flu Vaccine QIV 0.5mL | Seroconversion Rate | H3N2 | 64.29 percentage of participants |
| IL-YANG Flu Vaccine QIV 0.5mL | Seroconversion Rate | B/Yamagata | 55.36 percentage of participants |
| IL-YANG Flu Vaccine QIV 0.5mL | Seroconversion Rate | B/Victoria | 46.43 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroconversion Rate | B/Victoria | 14.29 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroconversion Rate | H1N1 | 64.29 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroconversion Rate | B/Yamagata | 35.71 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroconversion Rate | H3N2 | 53.57 percentage of participants |
Primary
Seroprotection Rate
Percentage of subjects achieving seroprotection\* for HI antibody after vaccination
Time frame: 28 days
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| IL-YANG Flu Vaccine QIV 0.5mL | Seroprotection Rate | H1N1 | 94.64 percentage of participants |
| IL-YANG Flu Vaccine QIV 0.5mL | Seroprotection Rate | H3N2 | 96.43 percentage of participants |
| IL-YANG Flu Vaccine QIV 0.5mL | Seroprotection Rate | B/Yamagata | 87.50 percentage of participants |
| IL-YANG Flu Vaccine QIV 0.5mL | Seroprotection Rate | B/Victoria | 78.57 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroprotection Rate | B/Victoria | 64.29 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroprotection Rate | H1N1 | 85.71 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroprotection Rate | B/Yamagata | 78.57 percentage of participants |
| IL-YANG Flu Vaccine TIV 0.5mL | Seroprotection Rate | H3N2 | 82.14 percentage of participants |
Secondary
GMR
Geometric Mean Ratio of post vaccination HI geometric mean titers
Time frame: 28 days
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| IL-YANG Flu Vaccine QIV 0.5mL | GMR | H3N2 | 6.90 Ratio of GMT titer |
| IL-YANG Flu Vaccine QIV 0.5mL | GMR | B/Brisbane | 3.20 Ratio of GMT titer |
| IL-YANG Flu Vaccine QIV 0.5mL | GMR | B/Massachusetts | 3.85 Ratio of GMT titer |
| IL-YANG Flu Vaccine QIV 0.5mL | GMR | H1N1 | 5.32 Ratio of GMT titer |
| IL-YANG Flu Vaccine TIV 0.5mL | GMR | B/Massachusetts | 2.90 Ratio of GMT titer |
| IL-YANG Flu Vaccine TIV 0.5mL | GMR | H3N2 | 6.73 Ratio of GMT titer |
| IL-YANG Flu Vaccine TIV 0.5mL | GMR | H1N1 | 8.41 Ratio of GMT titer |
| IL-YANG Flu Vaccine TIV 0.5mL | GMR | B/Brisbane | 2.00 Ratio of GMT titer |
Secondary
GMT
Geometric Mean Titer of post vaccination HI geometric mean titers
Time frame: 28 days
| Arm | Measure | Group | Value (GEOMETRIC_MEAN) |
|---|---|---|---|
| IL-YANG Flu Vaccine QIV 0.5mL | GMT | B/Brisbane | 52.52 HI titer of post vaccination |
| IL-YANG Flu Vaccine QIV 0.5mL | GMT | B/Massachusetts | 73.36 HI titer of post vaccination |
| IL-YANG Flu Vaccine QIV 0.5mL | GMT | H1N1 | 128 HI titer of post vaccination |
| IL-YANG Flu Vaccine QIV 0.5mL | GMT | H3N2 | 176.70 HI titer of post vaccination |
| IL-YANG Flu Vaccine TIV 0.5mL | GMT | B/Brisbane | 36.23 HI titer of post vaccination |
| IL-YANG Flu Vaccine TIV 0.5mL | GMT | H3N2 | 128.00 HI titer of post vaccination |
| IL-YANG Flu Vaccine TIV 0.5mL | GMT | H1N1 | 110.40 HI titer of post vaccination |
| IL-YANG Flu Vaccine TIV 0.5mL | GMT | B/Massachusetts | 51.24 HI titer of post vaccination |